Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has provided an update.
Giant Biogene Holding Co., Ltd. has proposed a final ordinary cash dividend of RMB 0.539 per share for the financial year ended 31 December 2025, underscoring its intention to return capital to shareholders. The dividend, subject to shareholder approval on 28 May 2026, will be paid in Hong Kong dollars on 25 June 2026, with the ex-dividend date set for 1 June 2026 and the record date on 8 June 2026.
The announcement provides a clear timetable for investors, including the last time to lodge share transfer documents on 2 June 2026 and a book closure period from 3 to 8 June 2026. By declaring a sizeable final dividend and outlining orderly distribution arrangements, the company signals confidence in its financial performance and offers income visibility to existing and prospective shareholders on the Hong Kong market.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
More about Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co., Ltd. is a Hong Kong-listed company in the biotechnology and healthcare sector. It focuses on developing and commercializing biogene-based products, with its shares traded on the Main Board of the Stock Exchange of Hong Kong, giving it access to regional and international investors.
Average Trading Volume: 5,282,517
Technical Sentiment Signal: Sell
Current Market Cap: HK$34.2B
See more data about 2367 stock on TipRanks’ Stock Analysis page.